Try our Advanced Search for more refined results
Life Sciences
-
March 13, 2026
Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit
Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.
-
March 13, 2026
4th Circ. Brings Back Allergan Medicaid Overcharging Suit
A split Fourth Circuit panel on Friday revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid by more than $680 million, saying the whistleblower plausibly alleged the company knowingly improperly aggregated discounts into "best prices" for drugs.
-
March 13, 2026
Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
Sandoz Inc. is appealing after a Virginia federal court ruled it should have brought claims accusing Amgen of blocking competition for the Enbrel biosimilar in a previous patent dispute, according to a Friday notice.
-
March 13, 2026
Kroger Agrees To Pay $17M In Drug Copay Inflation Case
Kroger pharmacy customers reached a $17 million settlement with the grocer resolving allegations that it inflated their copays for insured prescriptions, according to a motion for preliminary approval of the deal filed in Ohio federal court.
-
March 13, 2026
Life Sciences Partner Hiring Up Amid Regulatory Scrutiny
Large law firms' partner additions in life sciences rose slightly across five geographic markets between 2024 and 2025, with several factors including increased regulatory scrutiny driving new additions, according to an analysis by intelligence platform Macrae+.
-
March 13, 2026
J&J Unit Says Ex-Director Misappropriated Trade Secrets
A Johnson & Johnson subsidiary has accused a former associate director of downloading over 7,000 files worth of confidential information prior to her resignation and using it to start her own competing company.
-
March 12, 2026
Orthopedics Co. Investors See Merger Claims Trimmed
Orthofix Medical Inc. must face claims that it failed to tell investors that a company it was merging with recently settled class action discrimination allegations, but will not have to face some securities fraud allegations, a Texas federal judge has ruled.
-
March 12, 2026
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs
The D.C. Circuit spent more than three hours Thursday going round with Vanda Pharmaceuticals and the U.S. Food and Drug Administration about whether the label for a generic sleep-wake disorder medication is "the same" as the branded one because it doesn't include Braille.
-
March 12, 2026
Tom's Toothpaste Trims Class Action Over Lead Levels
Tom's of Maine can't beat back proposed class claims it allowed heavy metals to taint its children's toothpaste, a New York federal judge ruled Wednesday, finding that the parent behind the suit adequately claimed the company falsely marketed the products as "safe" and "healthy."
-
March 12, 2026
IP Notebook: TM Use Fight, Popeye, Kurt Cobain
This edition of emerging copyright and trademark cases and trends looks at an appeal before the U.S. Supreme Court that questions the definition of trademark "use in commerce" under the Lanham Act and a battle over the use of "Popeye" as a trademark.
-
March 12, 2026
Embryo Loss Suits Need 'Serious' Edits, Judge Told
Two complaints against fertility products maker CooperSurgical Inc. require "serious" amendments to clarify the nature of the claims that a defective culture medium caused embryo losses for in vitro fertilization patients, the company told a Connecticut federal judge Thursday.
-
March 12, 2026
US Chamber Report Warns Of Risks To IP Protection
While the U.S. has ranked at the top of the U.S. Chamber of Commerce's list measuring how countries worldwide are enforcing intellectual property laws, the group said problems with free trade agreements and efforts to reduce pharmaceutical prices could cause problems on the horizon domestically.
-
March 12, 2026
Epilepsy Drugmaker's Statements Insulated From Stock Suit
A Pennsylvania federal judge has trimmed a shareholder class action against Marinus Pharmaceuticals alleging it misled investors about the probability of success of an epilepsy drug, ruling that certain statements made by company leadership were immunized by the Private Securities Litigation Reform Act.
-
March 12, 2026
Del. Chancery Rejects Fraud Claims In $313.5M Fertilizer Deal
The Delaware Chancery Court has ruled that a group of investors failed to prove that executives and a private equity sponsor behind agricultural technology company Verdesian Life Sciences LLC defrauded them into investing in a 2014 acquisition, holding after trial that the claims were both time-barred and unsupported.
-
March 11, 2026
DNA Testing Co. Can't Shake Suit Over Genetic Data Sharing
A Massachusetts federal judge refused to release Nebula Genomics Inc. from a proposed class action accusing it of illegally sharing its customers' genetic information with Meta and other third parties through online tracking tools, finding that the parties' choice-of-law agreement didn't extend to the plaintiff's genetic privacy allegation.
-
March 11, 2026
Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud
An Illinois federal judge ordered Eli Lilly and Co. on Tuesday to arbitrate a dispute over millions of dollars in milestone payments allegedly owed under a collaboration agreement to develop an Alzheimer's disease drug, ruling that the drugmaker lacked standing to challenge an underlying security agreement.
-
March 11, 2026
New Wyoming Abortion Law Faces Familiar Legal Challenge
Just a day after it was signed into law, Wyoming's new anti-abortion law triggered a legal challenge from the same health clinic that successfully sued over the state's previous abortion limits.
-
March 11, 2026
La. Fights Dismissal Bid In Abortion Regulation Dispute
The state of Louisiana urged a federal court to deny motions by GenBioPro Inc. and Danco Laboratories seeking dismissal of its suit challenging federal regulation on mail-order abortion drugs, arguing it has established harms stemming from the regulations.
-
March 11, 2026
Insulin Makers Ask Justices To Review Collusion Case
Sanofi-Aventis US, Eli Lilly & Co., Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP have told the U.S. Supreme Court that a ruling reviving a case over insulin drug costs undermines key rules meant to weed out improper antitrust claims.
-
March 11, 2026
Pharma Co. Says Ex-Director Using Trade Secrets At New Job
A specialty infusion therapy pharmacy has accused a former director of contracts of taking valuable trade secrets with her on her way out to work for a rival company.
-
March 11, 2026
Bayer Sees 'Light At The End Of The Tunnel' In Roundup Suits
After more than a decade and tens of thousands of cases, a recent settlement announcement and a high-stakes high court hearing may finally give the makers of the weedkiller Roundup an off-ramp in seemingly never-ending litigation.
-
March 11, 2026
Pa. Justices Doubtful Law Unclear In AG-DA Opioid Deal Row
Multiple Pennsylvania Supreme Court justices on Wednesday doubted a state law was ambiguous about whether the attorney general could step in and settle claims brought by county-level district attorneys, as he had in a multistate settlement with opioid companies.
-
March 11, 2026
Anthem Beats Lab's $1.9M ERISA Payment Demand
Anthem Blue Cross Blue Shield of Connecticut has prevailed in a medical laboratory's $1.9 million contract and ERISA lawsuit over allegations the insurer refused to pay for out-of-network tests.
-
March 11, 2026
Minn. Lawmakers Advance Medical Psilocybin Bill
Minnesota lawmakers this week advanced a bipartisan bill to create a regulated medical program for psilocybin, the active ingredient in psychoactive mushrooms.
-
March 11, 2026
MoFo Private Equity Atty Joins Greenberg Traurig In Miami
Greenberg Traurig LLP announced Wednesday that a Miami-based private equity attorney has joined the firm's corporate practice from Morrison Foerster LLP.
Expert Analysis
-
Traditional FCA Enforcement Surges Amid Shifting Priorities
The U.S. Department of Justice’s January report on False Claims Act enforcement in fiscal year 2025 reveals that while the administration signaled its intent to expand FCA enforcement into new areas such as tariffs, for now the greatest exposure remains in traditional areas like healthcare — in which the risk is growing, say attorneys at Debevoise.
-
NYC Bar Opinion Warns Attys On Use Of AI Recording Tools
Attorneys who use artificial intelligence tools to record, transcribe and summarize conversations with clients should heed the New York City Bar Association’s recent opinion addressing the legal and ethical risks posed by such tools, and follow several best practices to avoid violating the Rules of Professional Conduct, say attorneys at Smith Gambrell.
-
Series
The Biz Court Digest: Dispatches From Utah's Newest Court
While a robust body of law hasn't yet developed since the Utah Business and Chancery Court's founding in October 2024, the number of cases filed there has recently picked up, and its existence illustrates Utah's desire to be top of mind for businesses across the country, says Evan Strassberg at Michael Best.
-
Checking In On Biologics-Related Patent Review Trends
Comprehensive analysis of Patent Trial and Appeal Board data since the PTAB's creation indicates that while inter partes review and post-grant review are potent weapons for challenging biologics-related patents, recent policy changes may reduce their effectiveness, say attorneys at Steptoe.
-
4 Quick Emotional Resets For Lawyers With Conflict Fatigue
Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.
-
Rescheduling Cannabis Marks New Tax Era For Operators
As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.
-
Navigating Trade Secret Exceptions In Noncompete Bans
Recent and ongoing developments in the noncompete landscape, including a potential decision from the Tenth Circuit in Edwards Lifesciences v. Thompson, could offer tools for employers to bring noncompete agreements within trade secret exceptions amid an era of heightened employee mobility, say attorneys at Sullivan & Cromwell.
-
Series
Playing Tennis Makes Me A Better Lawyer
An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.
-
Expect Major Shifts In Patent And Trademark Policy This Year
New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.
-
Class Actions At The Circuit Courts: January Lessons
In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.
-
Series
Judges On AI: How Judicial Use Informs Guardrails
U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.
-
What US Cos. Must Know To Comply With Italy's AI Law
Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.
-
Ag Bill Wording Presents Existential Threat To Hemp Industry
A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.
-
Series
Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief
My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.
-
5 Drug Pricing Policy Developments To Watch In 2026
2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.